Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.
Three recent panel discussions on renal cell carcinoma (RCC) treatment strategies from GU Oncology Now emphasized the evolving role of biomarkers, combination...
The underrepresentation of Black patients in past clinical studies assessing advanced renal cell carcinoma (aRCC) therapies means that researchers are ...
During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients with favorable-risk vs intermediate- or high-risk RCC, and how it changes their treatment options.
Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.
Background Immune checkpoint inhibitors (ICIs) are a cornerstone therapy for advanced renal cell carcinoma (RCC). However, significant rates of primary resistance hinder their efficacy, and the underlying mechanisms remain poorly understood. This study aims to unravel the tumor-immune ...
As the year comes to a close, we revisit some of this year’s top content on the management of renal cancer.
To evaluate the predictive utility of N6-methyladenosine (m6A)-associated long non-coding RNAs (lncRNAs) for the prognosis and immunotherapy response in papillary renal cell carcinoma (pRCC). Transcriptomic data of pRCC samples were extracted from the TCGA database. The m6A-related lncRNAs ...
The approval is supported by data from the phase 3 CheckMate-67T trial.
Adding nivolumab to treatment with tivozanib does not improve outcomes among patients with clear cell renal cell carcinoma (RCC) who have received ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.